Press release
November 5, 2026
Press releases
Browse our latest press releases below, or visit our investor site directly for a complete list of all recent and archived press releases.
Press release
November 5, 2026
Lantheus Reports Third Quarter 2026 Financial Results
Press release
November 2, 2026
Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer’s Disease Annual Meeting
Press release
September 30, 2026
Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)
Press release
September 28, 2026
Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer
Press release
September 22, 2026
Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for the Treatment of GEP-NETs
Press release
August 14, 2026
Lantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer’s Disease
Press release
August 6, 2026
Lantheus Reports Second Quarter 2026 Financial Results
Press release
August 3, 2026
Curium Announces Definitive Agreement to Merge with Lantheus
For access to press releases before 2022 and full-text search capabilities, please visit our investor site.